ARHGEF17

Across TCGA pan-cancer cohorts, ARHGEF17 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of ARHGEF17’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where ARHGEF17 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types ARHGEF17 is over-expressed in tumor, although a few such as LSCC and COAD show the opposite, repressed pattern.

LSCC, COAD, and LUAD are the cancer types where ARHGEF17 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ARHGEF17 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Male	II,III,IV	−0.909	<.001	9	view →
COAD	Male	III,IV	−0.669	<.001	9	view →
LUAD	Female	III,IV	−0.652	<.001	9	view →
CCRCC	Male	All	+0.287	<.001	7	view →
PDAC	All	All	+0.277	<.001	6	view →
HNSC	All	All	−0.155	<.001	6	view →
OV	All	All	−0.618	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

ARHGEF17–LSCC

Open the LSCC breakdown →